• Product NameSeratrodast
• Brief DescriptionInhibitors
• Purification98.93%
• Biological ActivitySeratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.
• Target NameCOX inhibitor; PPAR antagonist
• CAS No. 112665-43-7
• Calculated MW 354.44
• Formulation C22H26O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Respiratory system
  SMILES:CC1=C(C)C(=O)C(=C(C)C1=O)C1=CC(CCCCCCC(O)=O)=CC=C1
  Pathways:Immunology/Inflammation; Metabolism; Neuroscience
  Receptor:COX; TXA2R
  Boling pt:522.3C?
  Melting pt:118-120C
  Solubility:Soluble in Water
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Endo S, Akiyama K. Nihon Rinsho. 1996 Nov;54(11):3045-8.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting